biotech volatility drivers

Regulatory announcements remain one of the most decisive catalysts of market volatility in the US biotechnology and healthcare sectors. Unlike traditional industries, where earnings cycles dominate valuation shifts, biotech markets often respond abruptly to regulatory signals, particularly those issued by agencies such as the Food and Drug Administration and the Securities and Exchange Commission. These … Read more